Leap Therapeutics History
Our History
First patient dosed with TRX518 001
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
First patient dosed with TRX518 001
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer for TRX518
2006
2009
First US patent filed for TRX518
First patient dosed with DKN-01 by Eli Lilly
2010
First patient dosed with TRX518 at Memorial Sloan Kettering Cancer Center
2010
First US patent granted covering sequence of DKN-01
2016
Leap Therapeutics launched
2017
Leap Therapeutics becomes publicly listed on NASDAQ: LPTX
2017
Initiated collaboration with Merck to evaluate DKN-01 in combination with Keytruda
2018
Initiated collaboration with Pfizer/Merck KGaA to evaluate TRX518 in combination with Bavencio
2020
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01
Team
Luke Andersen
Finance
Peter Choi
Clinical
Lianna Cohen
Clinical
Liliana Cygan
Clinical
Michael Haas, Ph.D.
Research
Heidi Heath
Research
Peter Hocknell, Ph.D.
Manufacturing
Jerilynn Jacobson
Clinical
Michael Kagey, Ph.D.
Research
Gus Lawlor
Chief Operating Officer
Matthew Lederhos
Finance
Reena Lynam
Clinical
Jonathan Miller
Business Development
Chris Mirabelli, Ph.D.
President & CEO
Girish Naik, M.D.
Clinical
Lane Newman
Research
Walter Newman, Ph.D.
Senior Research Fellow
Alyssa Nicotra
Clinical
Mark O'Mahony
Vice President, Manufacturing
Douglas Onsi
Chief Financial Officer
Franziska
Schürpf-Huber
Research
Cyndi Sirard, M.D.
Vice President, Clinical
Robert Steinberg
Operations
Katie Woolford
Clinical
Board of Directors
Chris Mirabelli, Ph.D.
President & CEO, Leap Therapeutics
Chairman and CEO of Waypoint Holdings
John Littlechild
Managing Director at HealthCare Ventures
Co-Founder of NuBiyota
James Cavanaugh, Ph.D.
Managing Director at HealthCare Ventures
CEO and President of Angiogenesis Foundation
Joseph Loscalzo, M.D., Ph.D, M.A.
Chairman, Department of Medicine, Physician-in-Chief, Brigham and Women’s Hospital
Monica M. Bertagnolli, MD, FASCO
Chief, Division of Surgical Oncology, Dana-Farber/Brigham and Women's Cancer Center; Professor of Surgery, Harvard Medical School, Boston
Scientific Advisory Board
David Tuveson, M.D., Ph.D.
Chair of Leap SAB, Director of Research, the Lustgarten Foundation, Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory
Endowed Research Chair, Professor of Neurology, American Cancer Society Research Professor, Boston Children’s Hospital and Harvard Medical School
Christopher T. Walsh, M.D., Ph.D.
Hamilton Kuhn Professor of Biological Chemistry and Pharmacology at Harvard Medical School
Professor of Immunology and Infectious Disease at the Harvard T.H. Chan School of Public Health and Associate Professor of Medicine at Harvard Medical School. Physician at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA
Professor and Chairman of Department of Microbiology and Immunology at Weill Cornell Medical College
Senior Vice President and Chief Clinical Strategy Officer; Chief, Division of Women's Cancers, Dana Farber Cancer Institute; Director, Breast Oncology Program, Susan F. Smith Center for Women's Cancers; Thompson Chair in Breast Cancer Research Institute Physician; Professor of Medicine, Harvard Medical School